10X GENOMICS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 27.59 USD | +2.57% |
|
-1.25% | -50.70% |
| Apr. 18 | Deutsche Bank Cuts Price Target on 10x Genomics to $55 From $60, Keeps Buy Rating | MT |
| Mar. 26 | 10x Genomics, Inc. Commercially Launches Visium HD Spatial Gene Expression Assay | CI |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 7,333 | 15,237 | 16,640 | 4,171 | 6,615 | 3,288 | - | - |
| Enterprise Value (EV) 1 | 6,939 | 14,574 | 16,052 | 3,741 | 6,226 | 2,964 | 2,922 | 2,780 |
| P/E ratio | -95.3 x | -26.4 x | -281 x | -25 x | -25.7 x | -17.4 x | -29.8 x | -97.2 x |
| Yield | - | - | - | - | - | - | - | - |
| Capitalization / Revenue | 29.8 x | 51 x | 33.9 x | 8.08 x | 10.7 x | 4.85 x | 4.16 x | 3.54 x |
| EV / Revenue | 28.2 x | 48.8 x | 32.7 x | 7.24 x | 10.1 x | 4.37 x | 3.7 x | 3 x |
| EV / EBITDA | -295 x | -28 x | -516 x | -26.2 x | -27.1 x | -20 x | -39.7 x | 117 x |
| EV / FCF | -855 x | -57.2 x | -131 x | -22.6 x | -97.6 x | -28.6 x | -974 x | 32.7 x |
| FCF Yield | -0.12% | -1.75% | -0.76% | -4.42% | -1.02% | -3.49% | -0.1% | 3.06% |
| Price to Book | 17.5 x | 20.8 x | 20.5 x | 5.21 x | 9 x | 4.44 x | 3.68 x | 3.01 x |
| Nbr of stocks (in thousands) | 96,170 | 107,607 | 111,707 | 114,464 | 118,209 | 119,167 | - | - |
| Reference price 2 | 76.25 | 141.6 | 149.0 | 36.44 | 55.96 | 27.59 | 27.59 | 27.59 |
| Announcement Date | 2/18/20 | 2/17/21 | 2/16/22 | 2/15/23 | 2/15/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 245.9 | 298.8 | 490.5 | 516.4 | 618.7 | 677.8 | 789.6 | 928.2 |
| EBITDA 1 | -23.51 | -520.1 | -31.14 | -142.6 | -229.8 | -147.9 | -73.65 | 23.69 |
| EBIT 1 | -30.57 | -86.59 | -52.91 | -167.9 | -265.3 | -200.7 | -126.7 | -29.88 |
| Operating Margin | -12.43% | -28.98% | -10.79% | -32.52% | -42.88% | -29.62% | -16.05% | -3.22% |
| Earnings before Tax (EBT) 1 | -31.03 | -534.5 | -53.72 | -162 | -248.8 | -189.2 | -114.7 | -16.67 |
| Net income 1 | -31.25 | -542.7 | -58.22 | -166 | -255.1 | -188.4 | -114.1 | -23.34 |
| Net margin | -12.71% | -181.61% | -11.87% | -32.15% | -41.23% | -27.8% | -14.44% | -2.51% |
| EPS 2 | -0.8000 | -5.370 | -0.5300 | -1.460 | -2.180 | -1.582 | -0.9249 | -0.2839 |
| Free Cash Flow 1 | -8.115 | -254.6 | -122.7 | -165.3 | -63.8 | -103.5 | -3 | 85 |
| FCF margin | -3.3% | -85.18% | -25.01% | -32% | -10.31% | -15.27% | -0.38% | 9.16% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - | 358.76% |
| FCF Conversion (Net income) | - | - | - | - | - | - | - | - |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Announcement Date | 2/18/20 | 2/17/21 | 2/16/22 | 2/15/23 | 2/15/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q3 | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 125.3 | 143.5 | 114.5 | 114.6 | 131.1 | 156.2 | 134.3 | 146.8 | 153.6 | 184 | 142.1 | 157.1 | 176.9 | 201.9 | 173.1 |
| EBITDA 1 | -10.18 | -10.05 | -35.54 | -56.62 | -33.84 | -16.58 | -45.51 | -53.42 | -85.42 | -45.47 | -38.35 | -41.53 | -32.57 | -17.57 | -42.82 |
| EBIT 1 | -15.88 | -15.83 | -41.74 | -63.12 | -40 | -23.1 | -51.99 | -63.36 | -94.8 | -55.19 | -61.16 | -60.39 | -48.54 | -33.68 | -46.17 |
| Operating Margin | -12.67% | -11.03% | -36.45% | -55.07% | -30.51% | -14.78% | -38.71% | -43.15% | -61.7% | -30% | -43.05% | -38.44% | -27.44% | -16.68% | -26.66% |
| Earnings before Tax (EBT) 1 | -16.65 | -15.99 | -41.69 | -63.83 | -40.04 | -16.41 | -49.65 | -60.77 | -91.74 | -46.6 | -59.16 | -56.4 | -45.98 | -30.12 | -48.81 |
| Net income 1 | -17.17 | -18.45 | -42.41 | -64.46 | -41.91 | -17.22 | -50.75 | -62.41 | -92.99 | -48.95 | -58.35 | -55.36 | -44.33 | -29.11 | -49.17 |
| Net margin | -13.7% | -12.85% | -37.04% | -56.24% | -31.98% | -11.02% | -37.79% | -42.51% | -60.52% | -26.61% | -41.07% | -35.24% | -25.05% | -14.42% | -28.4% |
| EPS 2 | -0.1500 | -0.1600 | -0.3800 | -0.5700 | -0.3700 | -0.1500 | -0.4400 | -0.5300 | -0.7900 | -0.4100 | -0.4984 | -0.4715 | -0.3843 | -0.2531 | -0.4050 |
| Dividend per Share 2 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 11/3/21 | 2/16/22 | 5/4/22 | 8/8/22 | 11/2/22 | 2/15/23 | 5/3/23 | 8/3/23 | 11/2/23 | 2/15/24 | - | - | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - | - | - |
| Net Cash position 1 | 394 | 664 | 587 | 430 | 389 | 324 | 366 | 508 |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - | - |
| Free Cash Flow 1 | -8.12 | -255 | -123 | -165 | -63.8 | -104 | -3 | 85 |
| ROE (net income / shareholders' equity) | -31.2% | -93.6% | -7.48% | -20.5% | -33% | -26.6% | -7.33% | 4.74% |
| ROA (Net income/ Total Assets) | -8.56% | -70.7% | -5.98% | -16.2% | -25.6% | -14.7% | -4.8% | 2.78% |
| Assets 1 | 365.1 | 767.7 | 974.1 | 1,024 | 997.1 | 1,279 | 2,376 | -839.4 |
| Book Value Per Share 2 | 4.360 | 6.810 | 7.270 | 6.990 | 6.220 | 6.220 | 7.500 | 9.170 |
| Cash Flow per Share 2 | 0.8900 | -2.150 | -0.1900 | -0.3000 | -0.1300 | 0.3800 | 1.020 | 1.520 |
| Capex 1 | 42.7 | 36.7 | 101 | 132 | 48.6 | 22.7 | 24.8 | 26.9 |
| Capex / Sales | 17.38% | 12.27% | 20.65% | 25.5% | 7.85% | 3.35% | 3.13% | 2.9% |
| Announcement Date | 2/18/20 | 2/17/21 | 2/16/22 | 2/15/23 | 2/15/24 | - | - | - |
1USD in Million2USD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
D+
Sell
Buy
Mean consensus
BUY
Number of Analysts
16
Last Close Price
27.59
USD
Average target price
52.29
USD
Spread / Average Target
+89.51%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -50.70% | 3.29B | |
| +0.89% | 12.8B | |
| -10.29% | 7.61B | |
| +1.78% | 5.41B | |
| -1.16% | 4.51B | |
| +5.74% | 4.49B | |
| +12.21% | 2.73B | |
| -16.13% | 2.02B | |
| -11.50% | 1.73B | |
| -5.02% | 1.64B |
- Stock Market
- Equities
- TXG Stock
- Financials 10x Genomics, Inc.
